Press release archive | Oxurion — Advancing Science. Enhancing Vision

EN
NL

Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Press release archive

Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
3 Aug 2020
Oxurion NV Business Update - Q1 2020
7 May 2020
Oxurion NV – COVID-19 Statement
28 Mar 2020
Oxurion NV Business Update – FY 2019
12 Mar 2020
Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference
9 Feb 2020
Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference
5 Feb 2020
Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME
7 Jan 2020
Oxurion NV Announces the Passing of Dr. Claude Sander, Chief Legal Officer and Corporate Secretary to the Board
21 Dec 2019
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
19 Dec 2019
Oxurion NV Business Update – Q3 2019
18 Oct 2019
Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco
9 Oct 2019
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
9 Sep 2019
Oxurion NV Business Update – H1 2019
5 Sep 2019
Oxurion Completes Enrollment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)
4 Sep 2019
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
2 Sep 2019
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
20 Aug 2019
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
1 Jul 2019
ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies
11 Jun 2019
Oxurion NV - Data from Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
6 Jun 2019
Regulated information - Transparency Statement Clay
10 May 2019
Regulated information - Transparency Statement OXUR shares
10 May 2019
Oxurion NV Business Update – Q1 2019
8 May 2019
Oxurion NV to Present Further Preclinical Data at 2019 ARVO Meeting
26 Apr 2019
Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
24 Apr 2019
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule
4 Apr 2019
Oxurion NV Business Update – FY 2018
7 Mar 2019
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
28 Feb 2019
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
4 Feb 2019